Omalizumab

Details

Files

Generic Name:

Omalizumab

Project Status:

Cancelled

Therapeutic Area:

Asthma, severe persistent

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Brand Name:

Xolair

Project Line:

Reimbursement Review

Project Number:

SR0035-000

Submission Type:

Initial

Indications:

Asthma, severe persistent

Recommendation:

Request for reconsideration received on October 13, 2005 was deemed to include New Information (October 20, 2005). The drug will undergo review as a resubmission. A final Recommendation will not be issued at this time.

Files

Submission Status Report View PDF

Last Updated : April 18, 2005